MicroPort CardioFlow Medtech Corp. operates as a holding company with interest in developing medical devices. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2021-02-04. The Company’s main business is engaged in the research and development and commercialization of transcatheter and surgical solutions for structural heart diseases. The Company’s pipelines include transcatheter aortic heart valve implantation (TAVI) series products, AnchorMan left atrial appendage closure (LAAC) product, transcatheter mitral valve (TMV) products, transcatheter tricuspid valve (TTV) products and procedural accessories. The firm conducts its business in the domestic and overseas markets.
